|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HTRA2 |
Gene summary for HTRA2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HTRA2 | Gene ID | 27429 |
| Gene name | HtrA serine peptidase 2 | |
| Gene Alias | MGCA8 | |
| Cytomap | 2p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000422 | UniProtAcc | O43464 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27429 | HTRA2 | LZE4T | Human | Esophagus | ESCC | 5.46e-12 | 3.98e-01 | 0.0811 |
| 27429 | HTRA2 | LZE7T | Human | Esophagus | ESCC | 1.69e-03 | 1.81e-01 | 0.0667 |
| 27429 | HTRA2 | LZE8T | Human | Esophagus | ESCC | 2.09e-02 | 1.22e-01 | 0.067 |
| 27429 | HTRA2 | LZE20T | Human | Esophagus | ESCC | 1.96e-05 | 2.04e-01 | 0.0662 |
| 27429 | HTRA2 | LZE22T | Human | Esophagus | ESCC | 2.94e-03 | 2.95e-01 | 0.068 |
| 27429 | HTRA2 | LZE24T | Human | Esophagus | ESCC | 4.76e-29 | 6.79e-01 | 0.0596 |
| 27429 | HTRA2 | LZE21T | Human | Esophagus | ESCC | 1.07e-04 | 3.82e-01 | 0.0655 |
| 27429 | HTRA2 | LZE6T | Human | Esophagus | ESCC | 5.23e-04 | 3.43e-01 | 0.0845 |
| 27429 | HTRA2 | P1T-E | Human | Esophagus | ESCC | 9.80e-07 | 3.80e-01 | 0.0875 |
| 27429 | HTRA2 | P2T-E | Human | Esophagus | ESCC | 2.58e-38 | 7.47e-01 | 0.1177 |
| 27429 | HTRA2 | P4T-E | Human | Esophagus | ESCC | 9.34e-29 | 6.51e-01 | 0.1323 |
| 27429 | HTRA2 | P5T-E | Human | Esophagus | ESCC | 8.03e-18 | 3.84e-01 | 0.1327 |
| 27429 | HTRA2 | P8T-E | Human | Esophagus | ESCC | 7.24e-15 | 1.99e-01 | 0.0889 |
| 27429 | HTRA2 | P9T-E | Human | Esophagus | ESCC | 1.78e-16 | 3.34e-01 | 0.1131 |
| 27429 | HTRA2 | P10T-E | Human | Esophagus | ESCC | 3.10e-14 | 3.08e-01 | 0.116 |
| 27429 | HTRA2 | P11T-E | Human | Esophagus | ESCC | 1.55e-12 | 5.29e-01 | 0.1426 |
| 27429 | HTRA2 | P12T-E | Human | Esophagus | ESCC | 1.87e-32 | 6.05e-01 | 0.1122 |
| 27429 | HTRA2 | P15T-E | Human | Esophagus | ESCC | 1.40e-16 | 4.27e-01 | 0.1149 |
| 27429 | HTRA2 | P16T-E | Human | Esophagus | ESCC | 1.78e-37 | 6.71e-01 | 0.1153 |
| 27429 | HTRA2 | P17T-E | Human | Esophagus | ESCC | 1.48e-15 | 4.67e-01 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0072594110 | Esophagus | ESCC | establishment of protein localization to organelle | 311/8552 | 422/18723 | 3.02e-32 | 2.13e-29 | 311 |
| GO:0097193111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway | 222/8552 | 288/18723 | 5.87e-28 | 2.02e-25 | 222 |
| GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
| GO:001623617 | Esophagus | ESCC | macroautophagy | 216/8552 | 291/18723 | 1.94e-23 | 4.57e-21 | 216 |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:003238618 | Esophagus | ESCC | regulation of intracellular transport | 243/8552 | 337/18723 | 3.20e-23 | 7.25e-21 | 243 |
| GO:0006605111 | Esophagus | ESCC | protein targeting | 229/8552 | 314/18723 | 4.93e-23 | 1.01e-20 | 229 |
| GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
| GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
| GO:0006839110 | Esophagus | ESCC | mitochondrial transport | 187/8552 | 254/18723 | 8.35e-20 | 9.81e-18 | 187 |
| GO:1903829111 | Esophagus | ESCC | positive regulation of cellular protein localization | 199/8552 | 276/18723 | 2.99e-19 | 3.45e-17 | 199 |
| GO:0062197111 | Esophagus | ESCC | cellular response to chemical stress | 234/8552 | 337/18723 | 5.37e-19 | 5.97e-17 | 234 |
| GO:0033157110 | Esophagus | ESCC | regulation of intracellular protein transport | 169/8552 | 229/18723 | 3.31e-18 | 3.23e-16 | 169 |
| GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
| GO:0032388110 | Esophagus | ESCC | positive regulation of intracellular transport | 152/8552 | 202/18723 | 7.89e-18 | 7.36e-16 | 152 |
| GO:2001242111 | Esophagus | ESCC | regulation of intrinsic apoptotic signaling pathway | 128/8552 | 164/18723 | 1.75e-17 | 1.50e-15 | 128 |
| GO:0097191111 | Esophagus | ESCC | extrinsic apoptotic signaling pathway | 159/8552 | 219/18723 | 4.12e-16 | 2.94e-14 | 159 |
| GO:1904951111 | Esophagus | ESCC | positive regulation of establishment of protein localization | 216/8552 | 319/18723 | 1.01e-15 | 6.86e-14 | 216 |
| GO:2001234111 | Esophagus | ESCC | negative regulation of apoptotic signaling pathway | 161/8552 | 224/18723 | 1.24e-15 | 8.09e-14 | 161 |
| GO:0072655110 | Esophagus | ESCC | establishment of protein localization to mitochondrion | 97/8552 | 120/18723 | 2.17e-15 | 1.33e-13 | 97 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05012211 | Esophagus | ESCC | Parkinson disease | 201/4205 | 266/8465 | 1.56e-18 | 8.72e-17 | 4.46e-17 | 201 |
| hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa0421027 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
| hsa042156 | Esophagus | ESCC | Apoptosis - multiple species | 25/4205 | 32/8465 | 9.13e-04 | 2.92e-03 | 1.49e-03 | 25 |
| hsa05012310 | Esophagus | ESCC | Parkinson disease | 201/4205 | 266/8465 | 1.56e-18 | 8.72e-17 | 4.46e-17 | 201 |
| hsa0502238 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa0421037 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
| hsa0421511 | Esophagus | ESCC | Apoptosis - multiple species | 25/4205 | 32/8465 | 9.13e-04 | 2.92e-03 | 1.49e-03 | 25 |
| hsa0501214 | Liver | Cirrhotic | Parkinson disease | 158/2530 | 266/8465 | 3.62e-24 | 6.02e-22 | 3.71e-22 | 158 |
| hsa0502214 | Liver | Cirrhotic | Pathways of neurodegeneration - multiple diseases | 217/2530 | 476/8465 | 7.30e-14 | 2.03e-12 | 1.25e-12 | 217 |
| hsa042106 | Liver | Cirrhotic | Apoptosis | 58/2530 | 136/8465 | 9.84e-04 | 5.55e-03 | 3.42e-03 | 58 |
| hsa0501215 | Liver | Cirrhotic | Parkinson disease | 158/2530 | 266/8465 | 3.62e-24 | 6.02e-22 | 3.71e-22 | 158 |
| hsa0502215 | Liver | Cirrhotic | Pathways of neurodegeneration - multiple diseases | 217/2530 | 476/8465 | 7.30e-14 | 2.03e-12 | 1.25e-12 | 217 |
| hsa0421011 | Liver | Cirrhotic | Apoptosis | 58/2530 | 136/8465 | 9.84e-04 | 5.55e-03 | 3.42e-03 | 58 |
| hsa0501222 | Liver | HCC | Parkinson disease | 198/4020 | 266/8465 | 9.40e-20 | 1.58e-17 | 8.76e-18 | 198 |
| hsa0502222 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
| hsa042102 | Liver | HCC | Apoptosis | 83/4020 | 136/8465 | 9.51e-04 | 3.58e-03 | 1.99e-03 | 83 |
| hsa0501232 | Liver | HCC | Parkinson disease | 198/4020 | 266/8465 | 9.40e-20 | 1.58e-17 | 8.76e-18 | 198 |
| hsa0502232 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
| hsa042103 | Liver | HCC | Apoptosis | 83/4020 | 136/8465 | 9.51e-04 | 3.58e-03 | 1.99e-03 | 83 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HTRA2 | SNV | Missense_Mutation | novel | c.84N>T | p.Arg28Ser | p.R28S | O43464 | protein_coding | tolerated_low_confidence(0.32) | benign(0.007) | TCGA-JW-A5VG-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| HTRA2 | SNV | Missense_Mutation | rs201615648 | c.1031G>A | p.Arg344His | p.R344H | O43464 | protein_coding | deleterious(0.01) | probably_damaging(0.925) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| HTRA2 | SNV | Missense_Mutation | novel | c.191G>A | p.Gly64Glu | p.G64E | O43464 | protein_coding | deleterious_low_confidence(0) | benign(0.338) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| HTRA2 | SNV | Missense_Mutation | rs755545814 | c.1057N>A | p.Gly353Arg | p.G353R | O43464 | protein_coding | deleterious(0.04) | possibly_damaging(0.548) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| HTRA2 | deletion | Frame_Shift_Del | novel | c.370delN | p.Gly125ValfsTer84 | p.G125Vfs*84 | O43464 | protein_coding | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| HTRA2 | SNV | Missense_Mutation | rs746881352 | c.1156N>A | p.Asp386Asn | p.D386N | O43464 | protein_coding | tolerated(0.17) | probably_damaging(0.993) | TCGA-AJ-A8CT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HTRA2 | SNV | Missense_Mutation | novel | c.699N>T | p.Arg233Ser | p.R233S | O43464 | protein_coding | deleterious(0) | benign(0.179) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| HTRA2 | SNV | Missense_Mutation | rs772099633 | c.1295N>A | p.Arg432Gln | p.R432Q | O43464 | protein_coding | tolerated(0.17) | probably_damaging(0.986) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HTRA2 | SNV | Missense_Mutation | novel | c.1289N>T | p.Ala430Val | p.A430V | O43464 | protein_coding | tolerated(0.13) | probably_damaging(0.999) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| HTRA2 | SNV | Missense_Mutation | c.1078N>T | p.Arg360Cys | p.R360C | O43464 | protein_coding | deleterious(0.02) | benign(0.146) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |